#1 Clinical Trials Search in Europe

Human Papillomavirus Type 16 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna

This article summarizes several clinical trials investigating the use of the Human Papillomavirus (HPV) 9-valent vaccine, specifically focusing on the active substance Human Papillomavirus Type 16 L1 Protein. These trials aim to evaluate the vaccine’s safety, immunogenicity, and efficacy in different populations, including children, adolescents, adults, and individuals with specific medical conditions. The studies explore various dosing regimens, extended intervals between doses, and the vaccine’s potential in preventing HPV-related diseases and infections.

Table of Contents

What is the HPV Type 16 L1 Protein Vaccine?

The Human Papillomavirus (HPV) Type 16 L1 Protein vaccine is part of a 9-valent HPV vaccine called Gardasil 9. This vaccine helps protect against nine types of HPV, including type 16, which is one of the high-risk types most strongly associated with cervical cancer and other HPV-related cancers.[1]

The vaccine contains virus-like particles (VLPs) that mimic the HPV virus but do not cause infection. These VLPs are produced using recombinant DNA technology in yeast cells.[1]

How Does it Work?

When administered, the vaccine stimulates the body’s immune system to produce antibodies against the HPV L1 proteins. These antibodies help neutralize the actual virus if a person is later exposed, preventing infection. By protecting against HPV infection, the vaccine aims to reduce the risk of HPV-related diseases, including:

  • Cervical, vulvar, vaginal, and anal cancers
  • Precancerous lesions
  • Genital warts

Who is the Vaccine For?

The HPV vaccine is recommended for:

  • Girls and boys aged 9-14 years (primary target group for vaccination programs)[1]
  • Women up to age 45, especially those treated for cervical lesions[2]
  • Men up to age 45[3]
  • Immunocompromised individuals (special considerations may apply)[4]

Effectiveness

Clinical trials have shown the 9-valent HPV vaccine to be highly effective in preventing HPV infections and related diseases. Some key findings include:

  • High efficacy in preventing persistent HPV infections and cervical, vulvar, and vaginal precancerous lesions in women[1]
  • Potential reduction in recurrence of cervical lesions in women treated for high-grade cervical intraepithelial neoplasia (CIN)[2]
  • Effectiveness in preventing oral persistent HPV infections in adult males[3]

Dosing and Administration

The typical vaccination schedule involves:

  • 2 doses for individuals 9-14 years old, with the second dose given 6-12 months after the first[1]
  • 3 doses for individuals 15 years and older, given at 0, 2, and 6 months[1]

The vaccine is administered as an intramuscular injection, usually in the upper arm or thigh.

Safety and Side Effects

The HPV vaccine has been extensively tested and is considered safe. Common side effects may include:

  • Pain, swelling, or redness at the injection site
  • Headache
  • Fever
  • Nausea
  • Dizziness

Serious side effects are rare. As with any vaccine, severe allergic reactions are possible but extremely uncommon.[1]

Ongoing Research

Several clinical trials are currently investigating new applications and dosing regimens for the HPV vaccine:

  • Extended dosing intervals in young people to potentially reduce the number of doses needed[1]
  • Effectiveness in immunocompromised children and adolescents[4]
  • Use as a therapeutic vaccine in women with high-grade cervical lesions or early-stage cervical cancer[2]
  • Potential for treating difficult-to-treat palmar or plantar warts[5]

These ongoing studies aim to expand our understanding of the vaccine’s potential benefits and optimize its use in different populations.

Study Focus Population Key Objectives Main Endpoints
Extended dosing intervals Children and adolescents 9-14 years, young women 16-26 years Evaluate safety and immunogenicity of extended 2-dose regimens Antibody GMTs, seroconversion rates, adverse events
Immunocompromised patients Immunocompromised children and adolescents over 9 years Assess immunogenicity in various immunocompromised groups Seroconversion rates, antibody titers, immune response markers
Oral persistent infection Adult males 20-45 years Evaluate efficacy in preventing oral persistent HPV infection Incidence of HPV-related oral persistent infection, antibody responses
Vulvar HSIL treatment Women with vulvar HSIL Assess efficacy in preventing recurrence after treatment Recurrence rates, immune response, quality of life
Post-treatment vaccination Women over 45 with high-grade cervical lesions Evaluate impact on HPV clearance and disease recurrence HPV clearance rates, recurrence of cervical lesions
Palmar/plantar warts Patients with difficult-to-treat warts Assess efficacy in treating resistant palmar/plantar warts Complete remission rates, quality of life, pain reduction

FAQ

  • What is the main purpose of these HPV vaccine clinical trials? The main purpose of these clinical trials is to evaluate the safety, immunogenicity, and efficacy of the 9-valent HPV vaccine in various populations and scenarios. This includes testing different dosing regimens, extended intervals between doses, and its effectiveness in preventing HPV-related diseases and infections.
  • Who are the target populations for these HPV vaccine studies? The target populations vary across the studies but include children and adolescents aged 9-14 years, adult males aged 20-45 years, women over 45 years with high-grade cervical lesions, immunocompromised children and adolescents, and individuals with difficult-to-treat palmar or plantar warts.
  • What are some of the specific conditions being studied in relation to the HPV vaccine? The studies are investigating the vaccine's effectiveness in preventing or treating conditions such as high-grade cervical intraepithelial neoplasia (CIN2+), vulvar high-grade squamous intraepithelial lesions (vHSIL), oral persistent HPV infections, and difficult-to-treat palmar or plantar warts.
  • How is the vaccine's effectiveness being measured in these trials? The vaccine's effectiveness is being measured through various endpoints, including antibody responses, seroconversion rates, incidence of HPV-related infections and diseases, quality of life improvements, and in some cases, the clearance of existing HPV infections or related lesions.
  • Are there any safety concerns being addressed in these trials? Yes, all the trials include safety assessments as part of their objectives. This involves monitoring for adverse events, evaluating the tolerability of the vaccine, and assessing any potential risks associated with different dosing regimens or use in specific populations.

Ongoing Clinical Trials on Human Papillomavirus Type 16 L1 Protein – Adsorbed – In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna

Glossary

  • Human Papillomavirus (HPV): A group of viruses that can cause various types of cancer and genital warts. There are many types of HPV, and some are targeted by the 9-valent HPV vaccine.
  • 9-valent HPV vaccine: A vaccine that protects against nine types of HPV, including those most commonly associated with cervical cancer and genital warts.
  • Immunogenicity: The ability of a substance, such as a vaccine, to provoke an immune response in the body.
  • Seroconversion: The development of detectable antibodies in the blood directed against an infectious agent, indicating an immune response.
  • Cervical intraepithelial neoplasia (CIN): Abnormal changes in the cells on the surface of the cervix that could potentially lead to cervical cancer if left untreated.
  • Loop electrosurgical excision procedure (LEEP): A surgical procedure used to remove abnormal tissue from the cervix.
  • Vulvar high-grade squamous intraepithelial lesion (vHSIL): Abnormal, precancerous changes in the skin of the vulva.
  • Geometric Mean Titers (GMT): A measure of the average concentration of antibodies in a group of subjects, used to assess the immune response to a vaccine.
  • Competitive Luminex Immunoassay (cLIA): A laboratory test used to measure antibody levels in response to vaccination.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medical treatment or procedure.

References

  1. http://clinicaltrials.eu/trial-id/2022-500256-37-00
  2. http://clinicaltrials.eu/trial/study-on-hpv-vaccine-after-treatment-for-high-grade-cervical-lesions-in-women-over-45/
  3. http://clinicaltrials.eu/trial-id/2022-501974-21-00
  4. http://clinicaltrials.eu/trial-id/2022-501413-31-00
  5. http://clinicaltrials.eu/trial/study-on-the-effectiveness-of-the-nonavalent-hpv-vaccine-in-treating-hard-to-treat-palmar-or-plantar-warts-in-patients-who-have-not-responded-to-two-previous-treatments/